Do Commercial Interests Impact Clinical Science During a Public Health Emergency?

American Journal of Bioethics

Volumn 13, Issue 9, 2013, Pages 25-26

  Delva, Valerie ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; DRUG DEVELOPMENT; ETHICS; HUMAN; HUMAN EXPERIMENT; LEGAL ASPECT; MEDICAL RESEARCH; PANDEMIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS;

BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; ETHICS, RESEARCH; HUMANS; PANDEMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 84883475504     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2013.822132     Document Type: Article

References (8)

1. Cohen, D. 2009. Complications: Tracking down the data on oseltamivir. British Medical Journal, 339: 1342
2. Doshi, Peter, Jefferson, T. and Del Mar, C. 2012. The imperative to share clinical study reports: Recommendations from the Tamiflu experience. PLoS Med, 9 (4): e1001201
3. Edwards, S. 2013. Ethics of clinical science in a public health emergency: Drug discovery at the bedside. American Journal of Bioethics, 13 (9): 3 - 14.
4. Goldman, M., Compton, C. and Mittleman, B. B. 2013. Public-private partnerships as driving forces in the quest for innovative medicines. Clinical and Translational Medicine, 2: 2
5. Reich, M. R. 2000. Public-private partnerships for public health. Nature Medicine, 6: 617 - 620.
6. World Health Organization. 2011. Report of the review committee on the functioning of the international health regulations (2005) and on pandemic influenza A (H1N1) 2009 Available at: http://www.who.int/ihr/WHA64_10_HVF_2011.pdf (accessed July 9, 2013)
7. Witty, A. 2011. New strategies for innovation in global health: A pharmaceutical industry perspective. Health Affairs, 30: 118 - 126.
8. Zrin, D. A. and Tse, T. 2008. Moving towards transparency of clinical trials. Science, 319: 1340 - 1342.